GSK, the UK pharmaceutical group, is in advanced negotiations to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report cited by CNBC. The potential acquisition would be GSK's largest in over a decade and could be finalized as early as this week, though both parties have yet to reach a final agreement and talks could still fall apart due to last-minute hurdles [1]. The deal is expected to value Nuvalent between $9 billion and $10 billion, representing a premium of approximately 29% to 43% over Nuvalent's market capitalization of nearly $7 billion at Monday's close [1].
If completed, this transaction would be the second largest in GSK's history, following its 2014 asset swap with Novartis valued at $20 billion, and marks a significant shift from GSK's recent focus on smaller deals. GSK's new CEO, Luke Miels, who succeeded Emma Walmsley at the start of the year, previously indicated a preference for transactions in the £2 billion to £4 billion range, but this deal would far exceed that target. Since Miels' appointment was announced in September, GSK's share price has risen by roughly 29% [1].
Nuvalent's lead drug candidate, neladalkib, which targets certain types of lung cancer, is currently under FDA review with a decision deadline of November 27. Another drug, zidesamtinib, for ROS1-positive non-small cell lung cancer, is also under FDA review. Analysts at CGS International estimate that, if approved, these two drugs could generate combined annual revenues of $823 million by the 2029 financial year [1].
This potential acquisition comes amid a surge in biotech dealmaking, driven by factors such as looming patent cliffs and a renewed interest in public markets. According to PitchBook data, biotech deals globally have reached $106 billion across 201 transactions so far in 2026, positioning the sector for its strongest year since before the pandemic [1].
CONCLUSION
GSK's pursuit of Nuvalent signals a bold strategic shift under new leadership, aiming to strengthen its drug pipeline with high-potential oncology assets. The deal, if finalized, would have significant market implications and reflects the current wave of large-scale biotech acquisitions. Investors and analysts are closely watching for confirmation and regulatory outcomes that could further impact both companies.